Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) EPS (Basic) (2016 - 2026)

Oramed Pharmaceuticals filings provide 14 years of EPS (Basic) readings, the most recent being $0.23 for Q4 2025.

  • Quarterly EPS (Basic) rose 188.46% to $0.23 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.52 through Dec 2025, up 416.67% year-over-year, with the annual reading at $1.53 for FY2025, 418.75% up from the prior year.
  • EPS (Basic) hit $0.23 in Q4 2025 for Oramed Pharmaceuticals, down from $1.16 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $1.16 in Q3 2025 and bottomed at -$0.48 in Q3 2024.
  • Average EPS (Basic) over 5 years is $0.18, with a median of $0.22 recorded in 2024.
  • The largest annual shift saw EPS (Basic) surged 833.33% in 2024 before it crashed 575.0% in 2025.
  • Oramed Pharmaceuticals' EPS (Basic) stood at $0.78 in 2021, then plummeted by 60.26% to $0.31 in 2022, then grew by 6.45% to $0.33 in 2023, then tumbled by 178.79% to -$0.26 in 2024, then soared by 188.46% to $0.23 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's EPS (Basic) are $0.23 (Q4 2025), $1.16 (Q3 2025), and $0.32 (Q2 2025).